You are here
Roche Ends Development of Several Drugs
In an update on pharmaceutical pipeline projects tucked inside its financial results, FierceBiotech reports, Swiss drugmaker Roche announced that it was pulling the plug on several early- and late-stage candidates.
- Lampalizumab (RG7417), a phase 3 drug that last fall failed two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy due to age-related macular degeneration (AMD) and secondary to AMD. At one point, some analysts had predicted the drug could reach $2 billion in annual sales.
- RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma that was in phase 1 testing.
- RG6047, which was being tested in phase 1 for metastatic estrogen receptor-positive, HER2-negative breast cancer.
- RG7203, a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.
Source: FierceBiotech; February 1, 2018.